Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema

被引:54
作者
Figueroa, Marta S. [1 ]
Contreras, Ines [1 ]
Noval, Susana [1 ]
机构
[1] Hosp Ramon & Cajal, Dept Oftalmol, E-28034 Madrid, Spain
来源
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 2008年 / 28卷 / 03期
关键词
diabetic macular edema; diffuse macular edema; internal limiting membrane; triamcinolone acetonide; vitrectomy;
D O I
10.1097/IAE.0b013e318159e7d2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To prospectively determine the efficacy of vitrectomy combined with intravitreal triamcinolone acetonide (IVTA) injection, internal limiting membrane (ILM) peeling, or both in treating diffuse nontractional diabetic macular edema (ME). Methods: Patients with diffuse ME of <6 months who had no evidence of macular traction or macular ischemia were included in the study. Patients previously diagnosed with glaucoma underwent vitrectomy with ILM peeling. All other patients were randomly assigned to vitrectomy or vitrectomy with ILM peeling followed by IVTA injection. Results: Forty-two eyes of 38 patients were included in the study. Mean follow-up was 12 months. A statistically significant reduction in macular thickness was found at 1 month to 6 months, disappearing at 12 months. No differences in visual acuity between treatment groups were found during follow-up. Visual acuity improved in 5 (12%) of 42 eyes, remained unchanged in 32 (76%) of 42 eyes, and worsened in 5 (12%) of 42 eyes. Complications included increase in intraocular pressure in 8 (26%) of 31 eyes, mild vitreous hemorrhage in 6 (14%) of 42 eyes, central retinal pigment epithelium changes in 5 (12%) of 42 eyes, and cataract progression in 11 (38%) of 29 phakic eyes. Conclusion: In diffuse diabetic ME with no retinal traction, vitrectomy with either ILM peeling or IVTA injection at the end of surgery produces a short-term improvement in retinal thickness but no long-term anatomical or functional improvements.
引用
收藏
页码:420 / 426
页数:7
相关论文
共 41 条
[1]  
[Anonymous], 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI [DOI 10.1001/ARCHOPHT.1985.01050120030015, 10.1001/archopht.1985.01050120030015]
[2]   Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema [J].
Avci, R ;
Kaderli, B ;
Akalp, FD .
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2006, 34 (01) :27-32
[3]   Intravitreal triamcinolone acetonide for diabetic macular edema [J].
Chieh, JJ ;
Roth, DB ;
Liu, M ;
Belmont, J ;
Nelson, M ;
Regillo, C ;
Martidis, A .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2005, 25 (07) :828-834
[4]   THE LENS OPACITIES CLASSIFICATION SYSTEM-III [J].
CHYLACK, LT ;
WOLFE, JK ;
SINGER, DM ;
LESKE, MC ;
BULLIMORE, MA ;
BAILEY, IL ;
FRIEND, J ;
MCCARTHY, D ;
WU, SY .
ARCHIVES OF OPHTHALMOLOGY, 1993, 111 (06) :831-836
[5]   LOSS OF VISION BEFORE OPHTHALMIC REFERRAL IN BLIND AND PARTIALLY SIGHTED DIABETICS IN BRISTOL [J].
CLARK, JB ;
GREY, RHB ;
LIM, KKT ;
BURNSCOX, CJ .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1994, 78 (10) :741-744
[6]   Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema [J].
Dillinger, P ;
Mester, U .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2004, 242 (08) :630-637
[7]   Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown [J].
Edelman, JL ;
Lutz, D ;
Castro, MR .
EXPERIMENTAL EYE RESEARCH, 2005, 80 (02) :249-258
[8]   Intravitreal cortisone injection for refractory diffuse diabetic macular edema [J].
Er, H ;
Yilmaz, H .
OPHTHALMOLOGICA, 2005, 219 (06) :394-400
[9]   Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane [J].
Gandorfer, A ;
Messmer, EM ;
Ulbig, MW ;
Kampik, A .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2000, 20 (02) :126-133
[10]   Intravitreal triamcinolone for diffuse diabetic macular oedema [J].
Gibran, S. K. ;
Cullinane, A. ;
Jungkim, S. ;
Cleary, P. E. .
EYE, 2006, 20 (06) :720-724